Breaking News

Thermo Fisher, Agios Pharma to Co-develop Oncology CDx

To identify IDH gene mutations using Oncomine Precision Assay and the Ion Torrent Genexus System, a new sequencing solution.

By: Contract Pharma

Contract Pharma Staff

Thermo Fisher Scientific has expanded its strategic partnership with Agios Pharmaceuticals for the co-development of a second companion diagnostic (CDx) for oncology. The CDx will leverage the Oncomine Precision Assay, which runs on the new Ion Torrent Genexus System, and will be used globally to identify low-grade glioma (LGG) patients with isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) mutations who may be eligible for vorasidenib (AG-881). Vorasidenib is an investigational, oral, brain-pene...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters